CTA

Medigene presents streamlined 6-day, high stemness TCR-T therapy production process

Retrieved on: 
Giovedì, Aprile 25, 2024
CTA, Synovial sarcoma, Safety, Cytokine, MD, Stomach, DP, Interferon, PD-L1, CHI, Patient, Neoplasm, CSP, DPS, CTAS, TCR, Ovarian cancer, Vaccine

Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.

Key Points: 
  • Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.
  • This process is vital for producing effective, safe, and durable TCR-T therapies," stated Kirsty Crame, MD, VP Clinical Strategy & Development.
  • Medigene has developed a streamlined 6-day manufacturing process that focuses on the enrichment of CD8+ T cells whilst simultaneously maintaining a high degree of stemness.
  • Clinical indications for MDG1015 were primarily chosen based on the high unmet medical need, expression of the target antigen and/or PD-L1.

Ai For Alpha Launches Its New "CTA Flows Oracle" Technology

Retrieved on: 
Giovedì, Maggio 2, 2024
Technology, Finance, Fintech, Banking, Other Technology, Professional Services, Software, Data Analytics, Artificial Intelligence, Other Professional Services, CTA, Business development, Pension, Alpha

Ai For Alpha , a pioneering fintech specialized in AI investment strategies, announced the launch of its "CTA Flows Oracle" technology.

Key Points: 
  • Ai For Alpha , a pioneering fintech specialized in AI investment strategies, announced the launch of its "CTA Flows Oracle" technology.
  • The "CTA Flows Oracle" predicts flows of Managed Futures funds across all major asset classes.
  • This innovative approach leverages Ai For Alpha's unique technology for replicating hedge fund strategies.
  • Beatrice Guez, CEO of Ai For Alpha , detailed the innovation: "Two years ago, Ai For Alpha released its AI-powered CTA replication portfolios that have consistently replicated the returns of major CTA managers.

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Retrieved on: 
Mercoledì, Maggio 1, 2024
Technology, Biotechnology, Nanotechnology, Health, Other Health, Pharmaceutical, Stem Cells, Oncology, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Congress, CTA, EASL, Gene editing, IND, Entrepreneurship, CccDNA, Precision BioSciences, Precision, HBV

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Association for Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024 in Milan, Italy.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Association for Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024 in Milan, Italy.
  • “We look forward to the opportunity to share the latest new preclinical safety data from our PBGENE-HBV clinical candidate at the EASL Congress,” said Jeff Smith, Co-Founder and Chief Research Officer at Precision BioSciences.
  • PBGENE-HBV is designed to safely eliminate cccDNA and inactivate integrated HBV DNA.
  • As we look ahead, we remain on track to file an investigational new drug (IND) and/or clinical trial application (CTA) in 2024.”
    Presenter: Emily Harrison, Senior Scientist - Hepatitis Research Leader, Precision Biosciences

ComEd, Partners Announce Expanded Summer Job Training for Teens Interested in the Trades

Retrieved on: 
Mercoledì, Maggio 1, 2024
Oil, Gas, Energy, Other Education, Continuing, Training, Education, Philanthropy, Teens, Parenting, Fund Raising, Foundation, Family, Other Philanthropy, Other Energy, Consumer, Utilities, CTA, EVS, Learning, Goodwill Industries, Partnership, Student, Employment, Curriculum, Engineering, Commonwealth Edison, Workforce, Metro, Interest

Interested students are encouraged to apply through YMCA or Goodwill now through May 31.

Key Points: 
  • Interested students are encouraged to apply through YMCA or Goodwill now through May 31.
  • The program is one example of how ComEd is growing opportunities for local youth and residents to prepare for roles in the fast-growing clean energy sector in Illinois.
  • A recently commissioned study by ComEd , reveals that as many as 150,000 clean energy jobs will arrive in Illinois by 2050.
  • Those interested in applying for the program through the YMCA can learn more details and apply here .

Leading Laser Projector Brand Optoma Achieves WiSA SoundSend Certification

Retrieved on: 
Martedì, Aprile 30, 2024
Mobile, Wireless, Technology, Entertainment, Other Technology, Software, Audio, Video, General Entertainment, Hardware, Data Management, Consumer Electronics, Atmos, CTA, Consumer Technology Association, Certification, Sport, Research, UHD, WiSA, Television, DLP, Product management, Multimedia, Dolby Atmos

WiSA Association , a subsidiary of WiSA Technologies, Inc. (NASDAQ: WISA), and Optoma, the nation’s leading 4K UHD and DLP® laser projection brand*, announced today that its UHZ35ST, UHZ55 and UHZ66 4K UHD laser projectors have received WiSA SoundSend Certification.

Key Points: 
  • WiSA Association , a subsidiary of WiSA Technologies, Inc. (NASDAQ: WISA), and Optoma, the nation’s leading 4K UHD and DLP® laser projection brand*, announced today that its UHZ35ST, UHZ55 and UHZ66 4K UHD laser projectors have received WiSA SoundSend Certification.
  • The certification creates a benchmark for high quality audio experience and verifies projectors, TVs and other sources work flawlessly with the award-winning WiSA SoundSend wireless audio transmitter, as well as the anticipated WiSA SoundSend E launch.
  • View the full release here: https://www.businesswire.com/news/home/20240430911443/en/
    WiSA Association, a subsidiary of WiSA Technologies, Inc., and Optoma, the nation’s leading 4K UHD and DLP® laser projection brand, announced today that its UHZ35ST, UHZ55 and UHZ66 4K UHD laser projectors have received WiSA SoundSend Certification.
  • (Photo: Business Wire)
    “We are excited to achieve WiSA SoundSend Certification for the UHZ35ST, UHZ55 and UHZ66 4K UHD laser projectors and expand our line-up of solutions that seamlessly integrate with WiSA SoundSend wireless audio transmitters,” said Brian Soto, Director of Product Management, Optoma.

Gen Z Students Declare “This Is The Way” to Champion Accessibility, Preserve Endangered Indigenous Languages & Save the Planet

Retrieved on: 
Martedì, Aprile 30, 2024
Technology, Professional Services, Foundation, Philanthropy, Science, DEI (Diversity, Equity and Inclusion), Other Philanthropy, Engineering, Other Science, Other Education, Other Technology, Manufacturing, Sustainability, Primary, Secondary, Education, Environment, Artificial Intelligence, Congress, CTA, Lobbying, State, CMO, Public affairs, Intersection, Accessibility, D-DE, United Nations Security Council, Artificial intelligence, STEM, Generation Z, Gen, Brandywine High School, Policy, Regulatory affairs, DonorsChoose, Robotics, Communication, Tomorrow, Empathy, Hoover High School, Princeton High School, Corporate social responsibility, Mobile phone

Today, Samsung Electronics America named the three National Winners in the 14th annual Samsung Solve for Tomorrow competition.

Key Points: 
  • Today, Samsung Electronics America named the three National Winners in the 14th annual Samsung Solve for Tomorrow competition.
  • Every year, Solve for Tomorrow awards more than $2 million in Samsung technology and classroom supplies to participating public schools throughout the U.S.
  • Four additional Solve for Tomorrow awards were presented to the Gen Z student teams.
  • These distinguished lawmakers were also honored with STEM Champion Awards from Samsung in recognition of their efforts to advance STEM pursuits in their states.

Knotch Unveils Knotch One, First All-in-One Digital Optimization Platform for Content-Centric Web Experiences

Retrieved on: 
Mercoledì, Aprile 10, 2024
Blog, CTA, System, AI, Thought, Nielsen, Zillow, Content, B2C, SVP, B2B, Marketing, Growth, Fortune 1000, Online shopping

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- While on-stage at the Content Connect 2024 conference, Knotch today unveiled Knotch One, the first all-in-one digital optimization platform purpose-built to support today’s content-centric web experiences.

Key Points: 
  • NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- While on-stage at the Content Connect 2024 conference, Knotch today unveiled Knotch One, the first all-in-one digital optimization platform purpose-built to support today’s content-centric web experiences.
  • Content-centric web experiences are driving growth for B2B and B2C companies, alike.
  • “Today’s prospects and consumers demand content-centric website experiences, where every touch point throughout the customer journey is a value exchange,” said Knotch CEO Anda Gansca.
  • “That’s why we built Knotch One from the ground up to be the digital optimization platform that every marketing team needs to power its content engine.

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis

Retrieved on: 
Mercoledì, Aprile 10, 2024
CTA, PKM2, Partnership, Patient, Metabolism, Lilly, Inflammation, Immune system, Atopic dermatitis, Therapy

SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis, the most common inflammatory skin disease.

Key Points: 
  • SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis, the most common inflammatory skin disease.
  • SYX-5219 offers first-in-class potential as an oral, targeted, disease-modifying anti-inflammatory therapy, targeting a critical enzyme that regulates cell metabolism called pyruvate kinase M2 (PKM2).
  • Iain Kilty, Chief Scientific Officer of Sitryx, commented: “The nomination of SYX-5219 as our first clinical development candidate for atopic dermatitis is a hugely exciting development for Sitryx and an important milestone as we transition to a clinical-stage company.
  • The team has generated a strong preclinical data package that builds on the scientific community’s growing understanding of PKM2 and its role in the pathogenesis of atopic dermatitis.

New ON24 Report Reveals Significant Increase in Engagement as Digital Transformation Accelerates in the Financial Services Industry

Retrieved on: 
Martedì, Aprile 16, 2024
Software, Technology, Artificial Intelligence, Data Management, CTA, Marketing, Yoy, CMO, CTAS, B2B, Research, ON24, AI

Today, ON24 (NYSE: ONTF), a leading intelligent engagement platform for B2B sales and marketing, announced the release of its “2024 Financial Services Digital Engagement Benchmarks Report.” The comprehensive analysis unveils key digital engagement trends within the financial services sector, providing insights for marketers aiming to increase engagement with clients, agents and advisors, build thought leadership, generate demand and ultimately increase business results.

Key Points: 
  • Today, ON24 (NYSE: ONTF), a leading intelligent engagement platform for B2B sales and marketing, announced the release of its “2024 Financial Services Digital Engagement Benchmarks Report.” The comprehensive analysis unveils key digital engagement trends within the financial services sector, providing insights for marketers aiming to increase engagement with clients, agents and advisors, build thought leadership, generate demand and ultimately increase business results.
  • After analyzing interactions from thousands of financial services webinars and content experiences in 2023, the report reveals shifts in audience behavior and concludes that personalization is the biggest factor for driving business growth in the industry.
  • Financial services companies have seen an 18% increase in calls-to-action (CTA) engagement since 2022 and more than double the growth rate within personalized CTAs.
  • This trend is indicative of clients, agents and advisors’ increasing preference for online channels, highlighting the importance of a digital-first engagement strategy.

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Retrieved on: 
Martedì, Aprile 16, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, CTA, CRISPR, PMM, OTC, Gene editing, Partnership, Doctor of Philosophy, DMD, Prevail, Webcast, IND, Entrepreneurship, Novartis, DNA, Precision BioSciences, GLP, Eli Lilly and Company, CTAS, Toxicology, ID, Therapy, Precision, HBV, Vaccine

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
  • Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration.
  • The collaboration began in January 2021 and was amended in June 2023 to transfer certain preclinical research, manufacturing, and investigational new drug (IND)-enabling activities from Precision BioSciences to Prevail Therapeutics.
  • “We enjoyed a productive gene editing collaboration with Prevail Therapeutics and appreciate their contributions to the success of these programs.